As Cdk Global INC (CDK) Shares Rose, Shareholder Thompson Siegel & Walmsley LLC Increased Its Stake by $125.07 Million

CDK Global, Inc. (NASDAQ:CDK) Corporate Logo

Thompson Siegel & Walmsley Llc’s stake in Cdk Global Inc (CDK) is increased by 11701.9% based on its latest 2018Q4 regulatory filing with the SEC. The company’s stock popped up 16.38% while Thompson Siegel & Walmsley Llc bought 2.66 million shares. At the end of 2018Q4, the institutional investor held 2.68 million shares of the miscellaneous company, priced at $128.50M, up from 22,741 at the end of the previous reported quarter. Cdk Global Inc has $7.27 billion market cap. CDK touched $58.32 during the last trading session after $0.98 change.CDK Global, Inc. has volume of 496,898 shares. Since March 15, 2018 CDK has declined 13.56% and is downtrending. CDK underperformed by 17.93% the S&P 500.

Thompson Siegel & Walmsley Llc operates about $7.40 billion and $6.40 billion US Long portfolio. Its stake in Alleghany Corp (NYSE:Y) was decreased by 36,349 shares to 168,519 shares valued at $105.04M in 2018Q4, according to the filing. Thompson Siegel & Walmsley Llc has cut its stake in Ppl Corporation (NYSE:PPL) and also reduced its holding in Mednax Inc (NYSE:MD) by 100,012 shares in the quarter, for a total of 231,023 shares.

For more CDK Global, Inc. (NASDAQ:CDK) news released briefly go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “CDK Crosses Below Key Moving Average Level – Nasdaq” released on March 13, 2019, “CDK Global, Inc. (CDK) Ex-Dividend Date Scheduled for February 28, 2019 – Nasdaq” on February 27, 2019, “CDK Global (CDK) Jumps: Stock Rises 10% – Nasdaq” with a publish date: February 06, 2019, “Insiders Buy the Holdings of MDYV ETF – Nasdaq” and the last “Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales – Nasdaq” with publication date: March 01, 2019.

CDK Global, Inc. (NASDAQ:CDK) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.